Posted: Tue Nov 22, 2011 12:42 pm Post subject: GenQual Announces Initial Closing Of Its First Preferred Equ
GenQual Announces Initial Closing Of Its First Preferred Equity Funding Round
Released on: November 22, 2011, 10:55 am
Author: Jonathan Mirich
GenQual announces initial closing of its first preferred equity funding round
November 22, 2011- GenQual is pleased to announce initial closing of its first preferred equity round. Financial terms were not disclosed. This inaugural funding round allows GenQual to pursue proof-of-principle testing for its companion diagnostic approach for IL-6 mAb and other JAK/STAT inhibitors for autoimmune diseases and oncology indications. GenQual aims to prospectively identify responders for clinical-stage therapeutics to improve drug trial response rates and improve chances for drug approval. The round remains open for further funding.
GenQual Founder and CEO Jonathan Mirich said, “This funding round allows GenQual to pursue its business development goals to deliver companion diagnostics for very expensive IL-6 monoclonal antibody treatment for autoimmune disease, chiefly rheumatoid arthritis, as well as certain oncology indications. It allows us to extend collaborative agreements for proof-of-principle testing. We are very excited about the possibilities in this space.”
GenQual develops proprietary biomarker diagnostics for autoimmune and oncology indications. Our personalized medicine products are designed to facilitate early disease detection and diagnosis, and to improve treatment approaches at the molecular level. GenQual is a privately-held corporation based in the Seattle area.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum